Seung-Jung Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. The Last 10 Year TAVR Path and Achievement of ASAN MEDICAL CENTER
  2. Updated Techniques and Concepts 2021 for Complex Left Main PCI
  3. Why Mismatching? FFR vs. Angiographic %DS
  4. Minimalist TAVR: AMC Experience
  5. What Is the Practical Approach to LM/MVD Revascularization? - Make It Simple!!
  6. PREVENT: Physiology and Imaging for PREVENTing Future Events
  7. [Debate: Should All CTOs Be Opened?] Cons
  8. MAIN COMPARE: 10-Year Follow-up
  9. What Is the Benefit of CTO PCI?: Insights from the DECISION CTO
  10. Physiology-Guidance: Synergetic Hybrid Approach for Complex PCI
  11. 10-year Outcomes of MAIN-COMPARE Study: Main and Key Substudies
  12. [Featured Lecture] LM-PCI: New Techniques, Concept, and Insights from the LM Pioneer
  13. PCI vs CABG for Left Main and Multivessel Disease
  14. Integrated Use of FFR and IVUS in LM PCI
  15. TAVR in Asia, Korea, and AMC
  16. PREVENT Trial: Update and Interesting Cases
  17. The Lesson from DECISION-CTO Trial
  18. All the Data from IRIS-FFR Registry
  19. To Treat or Not to Treat for Gray Zone FFR(0.76-0.80)
  20. [Debate: Should All CTOs Be Opened?] Con
  21. Top 10 Tips on Left Main PCI
  22. Keynote Lecture on Left Main PCI: Expert\'s Concept and Technique
  23. Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward?
  24. Can BRS Stabilize Vulnerable Plaque?: PREVENT
  25. [Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease.
  26. How To Manage Grey Zone FFR?: Data from IRIS FFR Registry
  27. Impact of Complete Revascularization for Multivessel PCI
  28. PREVENT Trial: Update and Insight from Plaque Imaging
  29. Impact of Complete Revascularization for MVD PCI
  30. Why PCI ? - Rationale for PCI / - Patient & Lesion Selection
  31. Is It a Matter of Technique or Concept?: Left Main and Bifurcation PCI
  32. From STABLE to PREVENT
  33. FFR and Clinical Outcomes: Evidence Has Never Been Stronger
  34. Left Main PCI: The Simpler, The Better
  35. Case 1: Left Main Disease
  36. Left Main & Bifurcation PCI: Is It a Matter of Technique or Concept?
  37. Relationship Between FFR and Clinical Outcome: Data from IRIS-FFR Registry
  38. Can We Prevent Events of Vulnerable Plaques?: From STABLE to PREVENT
  39. FFR: How to Change Our Practice?
  40. Integrated Approach for LM PCI Using IVUS and FFR
  41. What Happened in Deferred Lesion: Insight from IRIS-FFR Registry
  42. Please Keep It: IVUS-Guidance for LM Stenting
  43. Left Main Disease Is Not Surgical Treatment Any More: Data-Supported 2015
  44. Fate of Deferred Lesion: Insight from Prospective IRIS-FFR Registry
  45. Plaque Stabilization and Preemptive BVS: From STABLE to PREVENT
  46. How to Treat? - Functionally Insignificant Vulnerable Plaque: STABLE and PREVENT
  47. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
  48. Can We Prevent Future Event?: PREVENT Trial - Design and Rationale
  49. Impact of FFR
  50. IVUS Is Enough!
  51. How Good FFR Guided in Real Practice from Asan PCI and Multivessel Registry & IRIS-FFR Registry
  52. Can We Prevent DEFER Lesion Event? PREVENT Trial - Design and Rationale
  53. Asian Multicenter Registry
  54. FFR Guided Clinical Practice of Left Main PCI
  55. [FFR Use at CathLab: More & Better] FFR-guided PCI in Routine Practice: Lessons from the AMC Experience
  56. Temporal Trends and Outcomes of Contemporary LM Treatment: From the Asan Left Main Registry
  57. Either FFR or IVUS Is Acceptable, but Choose Your Cutoff Values Wisely!
  58. 15-year Temporal Change of LM Revascularization: Lesson from Asan Main Registry
  59. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - No, I Don\'t. We Can\'t Predict Fate of Vulnerable Plaque.
  60. Meta-analysis of LM PCI: PCI Using DES vs. CABG
  61. How Good FFR Guided in Real Practice: Data from Asan PCI and Multivessel Registry
  62. IVUS-MLA and FFR
  63. Coronary Angiography versus FFR: Why Mismatches
  64. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't
  65. TAVI in Korea: How to Avoid Conduction Disturbance..
  66. PCI vs CABG from BARI to SYNTAX: Is the Game over?
  67. Functional Evaluation Is Necessary !
  68. Trend in Outcomes of Percutaneous Coronary Intervention with the Integrated Use of Fractional Flow Reserve and Intravascular Ultrasound
  69. Impact of Functional Angioplasty in Our Real Practice!
  70. Impact of Functional Angioplasty to Current Practice: Trends in Clinical Outcomes of PCI with Drug Eluting Stents
  71. Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM
  72. Now, Do the IVUS-MLA Criteria Need to Be Adjusted ?
  73. When and How We Utilize Imaging and Functional Information in LM Stenting
  74. Clinical Outcomes from RCTs and Registries
  75. Why Visual-functional Mismatch? New Insight from Computational Simulation and Imaging Data
  76. New Frontiers in Left Main Intervention; Functional Angioplasty and New Optimizing Criteria
  77. Why Visual-functional Mismatches?
  78. FFR Guided and IVUS Supported Functional Angioplasty
  79. Device Positioning Is Crucial.
  80. Functional PCI for LM Stenosis: IVUS and FFR Guided
  81. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] Yes, Already Proven.
  82. Functional Angioplasty - Insight from FFR and IVUS
  83. Why Visual-Functional Mismatches?
  84. Invited Case Presentation & Focus Review: FFR Guided Spot Stenting for Tandem Lesion PCI
  85. Discrepancy between Anatomic vs. Functional Parameters (IVUS vs. FFR)
  86. It's Not Enough !
  87. Long and Tandem Lesion Intervention: FFR Guided Spot Stenting
  88. Pre-COMBAT: LM Disease Revascularization - PCI vs. CABG Randomization Study
  89. Is Angiography Enough To Guide LMT PCI? - 'Functional Approach Should Be Considered!'
  90. Left Main PCI: Where We Are? Where We Are Going?
  91. Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
  92. Anatomic vs. Functional Assessment of Coronary Artery Stenosis: Can IVUS-Derived Minimal Lumen Area Predict FFR < 0.8?
  93. Case Based Learning
  94. Paradigm Shift to Functional Angioplasty: FFR Guided Decision Making, IVUS Guided Optimization
  95. PCI in Unprotected Left Main Disease (MAIN-COMPARE, SYNTAX, and Several Registries)
  96. Xience V in Real Life
  97. Duration of Dual Antiplatelet Therapy in DES
  98. Insight into LM PCI from Main-COMPARE, SYNTAX LM, and Registries
  99. Coronary Intervention
  100. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  101. DECISION CTO_New Horizon in CTO Treatment; Randomized Study Proposal
  102. Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial
  103. Future Clinical Study for Nobori Stent in Korea
  104. The Impact of Diabetes in the DES Long-Term Outcome
  105. Prognostic Influence of DM on Long-Term Clinical Outcomes and Stent Thrombosis Following DES Implantation in Asian: AMC Experience
  106. Can SYNTAX Score Be Feasible to Predict Outcomes of LM Revascularization?: Application to MAIN-COMPARE Registry
  107. Can Carotid Artery Stenting Before CABG Reduce Perioperative Stroke ?
  108. Tailores Approach with DES for Long Coronary Lesions
  109. \"ZEST\" Trial
  110. PCI vs CABG in Left Main Disease: Main Registry Update
  111. Impact of Diabetes on Long-Term Outcomes of Drug-Eluting Stents in Asian Patients
  112. Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry
  113. How Can We Optimize Good Result in the Long Coronary Lesion ?
  114. Left Main Trifurcation Intervention
  115. LM Intervention Is Still an Available Option Despite Late Stent Thrombosis?
  116. VH-IVUS: Matched and Mismatched
  117. Nobori Stent, Update
  118. VH Experience in Real World: Asan Medical Center
  119. How to Treat - Unprotected Left Main Disease
  120. LM Bifurcation Intervention Guideline for COMBAT
  121. Safety and Efficacy of Cypher on Complex Lesion
  122. LM stenting -Cypher
  123. Drug Eluting Stent: Real World Experience(AMC Registry Study)
  124. Long Cypher Multicenter Registry Study
  125. Aggressive Colesterol Lowering Therapy after PCI(Percutaneous Coronary Intervention)
  126. Long-DES: Study presented in TCT 2004
  127. Treatment of In-Stent Restenosis : Drug Eluting Stent versus Brachytherapy
  128. Is bypass surgery needed for elderly patients with left main coronary artery disease? - CON l
  129. Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis
  130. Long Cypher?Multicenter Registry Study in Korea
  131. Bail-out stenting for Unprotected Left Main Coronary Artery Dissection during Catheter-Based Procedure
  132. Cypher vs. Taxus ; Taxus vs. Cypher - Is there something different ?
  133. Primary Stenting for Unprotected Left Main Coronary Artery Stenosis during AMI
  134. Percutaneous Mitral Valvuloplasty: State of Art
  135. Coronary Perforation of Proximal LAD after Debulking for LMCA Ostial Stenosis, Treated with PTEE-covered JoStent
  136. Why Polymer Coated Paclitaxel Stents
  137. Percutaneous Intervention of Unprotected left main Disease
  138. Technical Feasibility, Safety, and Clinical Outcome of Stenting of Unprotected Left Main Coronary Artery Bifurcation Narrowing Equipment Overview of DCA Device Percutaneous Intervention of Unprotected Left Main Disease
  139. PCI for Chroic Total Occlusion
  140. Drug-Eluting Stent
  141. Left Main Ostial Stenosis after Aortic Valve Replacement
  142. Percutaneous Intervention of Unprotected Left Main Ostial and Shaft Disease